Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 11—November 2011
CME ACTIVITY - Research

Global Distribution and Epidemiologic Associations of Escherichia coli Clonal Group A, 1998–2007

James R. JohnsonComments to Author , Megan E. Menard, Tsai-Ling Lauderdale, Chris Kosmidis, David Gordon, Peter Collignon, Joel N. Maslow, Arjana Tambić Andrašević, and Michael A. Kuskowski
Author affiliations: Veterans Affairs Medical Center, Minneapolis, Minnesota, USA (J.R. Johnson, M.E. Menard, M.A. Kuskowski); University of Minnesota, Minneapolis (J.R. Johnson, M.A. Kuskowski); National Health Research Institutes, Zhunan, Taiwan (T.-L. Lauderdale); University of Athens Medical School, Athens, Greece (C. Kosmidis); Australian National University, Canberra, Australian Capital Territory, Australia (D. Gordon, P. Collignon); Canberra Hospital, Canberra (P. Collignon); Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA (J.N. Maslow); University of Pennsylvania, Philadelphia (J.N. Maslow); University Hospital for Infectious Diseases, Zagreb, Croatia (A. Tambić Andrašević)

Main Article

Table 4

Prevalence of clonal group A, by clinical/host variables, among 2,210 extraintestinal Escherichia coli isolates from 32 globally distributed centers, 1998–2007*

Clinical/host variable and year isolate obtained from patient clinical specimen No. clonal group A isolates/total no. isolates (%)† p value‡
Total TMP/SMZ susceptible TMP/SMZ resistant
Specimen type
Nonurine 48/653 (7.4) 9/318 (2.8) 39/335 (11.6) <0.001
Urine 88/1,470 (6.0) 21/739 (2.8) 67/731 (9.2) <0.001
Host age group, y
<18 16/250 (6.4) 4/118 (3.4) 12/132 (9.1) 0.08
>18 122/1,909 (6.4) 25/938 (2.7) 97/971 (10.0) <0.001
Host hospital status
Outpatient 84/1,135 (7.4) 17/573 (3.0) 67/562 (11.9) <0.001
Inpatient 54/926 (5.8) 13/434 (3.0) 41/488 (8.4) <0.001
Year isolated
1998–2002 95/1,330 (7.1) 21/661 (3.2) 74/669 (11.1) <0.001
2003–2007 49/880 (5.6) 9/422 (2.1) 40/458 (8.7) <0.001

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†Data for each clinical variable include only isolates for which status with respect to the particular variable was known.
‡p values, by Fisher exact test, for comparisons of TMP/SMZ-susceptible vs. -resistant isolates within each subgroup. For all comparisons between subgroups within a given category (whether overall or by TMP/SMZ phenotype), p>0.10.

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†Data for each clinical variable include only isolates for which status with respect to the particular variable was known.
‡p values, by Fisher exact test, for comparisons of TMP/SMZ-susceptible vs. -resistant isolates within each subgroup. For all comparisons between subgroups within a given category (whether overall or by TMP/SMZ phenotype), p>0.10.

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†Data for each clinical variable include only isolates for which status with respect to the particular variable was known.
‡p values, by Fisher exact test, for comparisons of TMP/SMZ-susceptible vs. -resistant isolates within each subgroup. For all comparisons between subgroups within a given category (whether overall or by TMP/SMZ phenotype), p>0.10.

Main Article

1Investigators who contributed data are listed at the end of this article.

Page created: October 21, 2011
Page updated: October 21, 2011
Page reviewed: October 21, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external